Core Viewpoint - Winter is a peak season for migraines, and acupuncture is recommended as an effective treatment alternative to painkillers, which can have side effects [1] Group 1: Acupuncture Benefits - Acupuncture is based on the theory of human meridians and effectively stimulates specific acupoints to adjust the body's blood and energy flow [1] - Clinical practice shows significant improvement in migraine symptoms for many patients after acupuncture treatment, leading to reduced frequency and intensity of pain [1] - Unlike medication, acupuncture is safe and does not impose additional burdens on the body, avoiding potential harm from drugs [1]

Core Insights - The core viewpoint of the article emphasizes the growth potential of the global market for Succinic Acid Furoate Tablets, which is projected to increase from $31.15 million in 2024 to $38.43 million by 2031, reflecting a CAGR of 3.47% from 2024 to 2031 [1]. Market Overview - The global market for Succinic Acid Furoate Tablets is characterized by a dual structure of original research drugs and generics, with a mature segment in the triptan class of migraine treatments [1]. - In developed regions like the US and Europe, the product maintains stable demand due to guideline recommendations and extensive insurance coverage [1]. - In the Asia-Pacific region, particularly in China and India, the entry of local generic manufacturers is driving rapid market penetration, significantly enhancing drug affordability and accessibility [1]. - Overall market competition is primarily driven by pricing strategies and channel expansion [1]. Production and Quality Control - The production process for Succinic Acid Furoate Tablets requires high standards, utilizing excipients such as lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, sodium carboxymethyl starch, magnesium stearate, and specialized film coating premixes [2]. - These excipients play a crucial role in stability, bioavailability, and patient compliance, highlighting the importance of quality control and CGMP compliance [2]. - Major manufacturers include Endo Pharmaceuticals, Menarini, Ingenus Pharmaceutical, and Glenmark, which rely on advanced production facilities and strict quality management systems to ensure stable supply and compliance with global regulatory standards [2]. Market Dynamics - Epidemiological data indicates that the global prevalence of migraines is still rising, with increasing diagnosis and treatment rates in emerging markets [2]. - The introduction and application of new therapies such as CGRP monoclonal antibodies and oral CGRP antagonists pose a substitution pressure on traditional triptan drugs [2]. - In mature markets, the market share of Succinic Acid Furoate Tablets may gradually decline, but they are expected to maintain a solid position in regions with limited insurance coverage and price sensitivity [2]. Competitive Landscape - The top 11 manufacturers in the global Succinic Acid Furoate Tablets market and their market shares are based on 2024 survey data, with the leading companies including Endo International, Menarini, Ingenus Pharmaceuticals, and Glenmark [3]. - In 2024, the top five manufacturers are expected to hold approximately 11.0% of the market share [5].

Core Viewpoint - A diabetes drug, Liraglutide, has shown promise in reducing the frequency of debilitating migraines, potentially paving the way for a new treatment approach that targets intracranial pressure rather than just symptom management [3][4][7][20]. Group 1: Study Overview - The study involved 31 obese adults with high-frequency or chronic migraines who had not responded to at least two preventive treatments [10]. - Participants received daily subcutaneous injections of Liraglutide, starting at 0.6 mg and increasing to 1.2 mg over 12 weeks, while continuing existing migraine treatments [12]. - The study was conducted in Naples, Italy, from January to July 2024 [10]. Group 2: Results - After 12 weeks, the average number of headache days per month decreased significantly from 19.8 days to 10.7 days, a reduction of 9.1 days [15]. - Nearly half (48%) of participants experienced at least a 50% reduction in headache frequency, and 23% had a reduction of 75% or more [16]. - The MIDAS score, which measures migraine-related disability, dropped from 60.4 to 28.6, indicating significant improvement in daily functioning [17]. - The participants' BMI showed a slight decrease from 34.0 to 33.9, confirming that the reduction in headache frequency was not related to weight loss [18]. Group 3: Mechanism and Implications - The study suggests that Liraglutide may lower migraine frequency and severity by regulating intracranial pressure and modulating CGRP levels, rather than merely causing weight loss [19][23]. - This research represents a novel treatment strategy, differing from current migraine prevention drugs that focus on blocking CGRP action rather than preventing its release [20]. Group 4: Limitations and Future Research - The study has limitations, including its open-label design, small sample size, lack of a control group, and relatively short follow-up period, indicating the need for further research to validate these findings [21]. - Experts emphasize the necessity for more rigorous clinical trials before Liraglutide can be widely recommended for migraine treatment [26][28].

Core Viewpoint - The article discusses a clinical trial indicating that the GLP-1 receptor agonist Liraglutide may significantly reduce the frequency of migraine attacks in obese patients suffering from migraines, with a reported reduction of nearly 50% in monthly migraine occurrences [1][3][8]. Group 1: Clinical Trial Insights - The clinical trial is the first to explore the potential of GLP-1 receptor agonists in migraine suppression [3][4]. - The study involved 31 participants with chronic migraines and obesity (BMI > 30 kg/m²), all of whom had previously tried at least two preventive migraine medications without success [8]. - After 12 weeks of Liraglutide treatment, participants reported a decrease in average headache days from nearly 20 to less than 11 per month, with 15 participants experiencing at least a 50% reduction in headache frequency [8]. Group 2: Mechanism and Future Research - The research team suggests that the alleviation of migraines may not be solely due to weight loss, as participants did not experience significant weight changes during the trial, indicating that Liraglutide may act more directly on pain pathways [9]. - A hypothesis is proposed that slight increases in intracranial pressure could be a potential mechanism for migraine onset, with GLP-1 drugs shown to reduce intracranial pressure in animal studies [10]. - Plans for a larger randomized controlled trial are underway to validate the hypothesis, which will also measure changes in intracranial pressure in relation to headache relief [11].

Core Viewpoint - The article discusses the advancements in migraine treatment, particularly focusing on the drug Ubrogepant, which has shown potential in alleviating prodromal symptoms before migraine attacks, marking a significant development in migraine management [1][2]. Group 1: Migraine Overview - Migraine is a common neurological disorder characterized by debilitating attacks that include headache and brain function impairment, with recognized phases: prodromal, aura, headache, and postdrome [1]. - Symptoms during the prodromal and aura phases can include sensitivity to light and sound, nausea, neck pain, and dizziness, leading to significant functional impairment for migraine sufferers [1]. Group 2: Ubrogepant's Clinical Research - A large-scale, randomized, placebo-controlled phase 3 clinical trial published in Nature Medicine demonstrated that Ubrogepant can reduce common non-headache symptoms during the prodromal phase of migraines [2][4]. - The study involved 438 participants aged 18-75 with a history of migraines, who were administered 100 mg of Ubrogepant or a placebo after the onset of prodromal symptoms [4]. Group 3: Efficacy of Ubrogepant - Results indicated that Ubrogepant significantly improved attention, reduced photophobia, fatigue, and neck pain within hours of administration compared to the placebo group [4][5]. - Specifically, 19.5% of participants in the Ubrogepant group did not experience photophobia after 2 hours, compared to 12.5% in the placebo group; 27.3% versus 16.8% for fatigue after 3 hours; and 50.7% versus 35.8% for phonophobia after 4 hours [5]. Group 4: Implications for Treatment - The findings suggest that taking Ubrogepant during the prodromal phase may effectively alleviate common symptoms, with improvements observable as soon as one hour after administration [6].